Evidence map›Paper›PMID 32391256›Full record

ArticleFrontiers in oncology2020

Upregulated MELK Leads to Doxorubicin Chemoresistance and M2 Macrophage Polarization via the miR-34a/JAK2/STAT3 Pathway in Uterine Leiomyosarcoma.

Zhiwei Zhang, Chenggong Sun, Chengcheng Li, Xinlin Jiao, Brannan B Griffin, Samina Dongol, Huan Wu, Chenyi Zhang, Wenyu Cao, Ruifen Dong and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Targeting MELK in tumor cells and tumor microenvironment: from function and mechanism to therapeutic application.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Possible Role of IL-6R/STAT3/MiRNA-34a Feedback Loop in Osteosarcoma.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Zhiwei ZhangDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Chenggong SunDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Chengcheng LiDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Xinlin JiaoDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Brannan B GriffinDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Samina DongolDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Huan WuDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Chenyi ZhangDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Wenyu CaoDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Ruifen DongDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Xingsheng YangDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Qing ZhangDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Beihua KongDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.
Qilu Hospital of Shandong University · CNNorthwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uterine leiomyosarcoma (ULMS) is the most lethal gynecologic malignancy with few therapeutic options. Chemoresistance prevails as a major hurdle in treating this malignancy, yet the mechanism of chemoresistance remains largely unclear. In this study, we certified MELK as a poor prognostic marker through bioinformatic analysis of the GEO database. Cellular experiments

Indexed as

apoptosischemoresistanceJAK2M2 macrophageMELKSTAT3uterine leiomyosarcoma

Identifiers

PMID32391256
PMCPMC7188922
OpenAlexW3019563684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.